Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alpha in compensated chronic hepatitis B cirrhosis
ChiCTR2400088691Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) and Cirrhosis (4 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: HBsAg negative conversion rate, Liver fibrosis stage change (METAVIR score) and 3 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)Cirrhosis
Beyond the preview
Go deeper on ChiCTR2400088691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088691.